Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct 20;173(8):683.
doi: 10.7326/L20-1097.

The Unrecognized Prevalence of Primary Aldosteronism

Anand Vaidya  1 , Jenifer M Brown  1 , Robert M Carey  2 , Mohammed Siddiqui  3 , Gordon H Williams  1
Affiliations
Comment

The Unrecognized Prevalence of Primary Aldosteronism

Anand Vaidya et al. Ann Intern Med. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The spectrum of subclinical primary aldosteronism and incident hypertension. A cohort study. Ann Intern Med. 2017;167:630–41. [PMID: 29052707] doi:10.7326/M17-0882. - DOI - PMC - PubMed
    1. Carey RM, Douglas JG, Schweikert JR, et al. The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone. Arch Intern Med. 1972;130:849–54. [PMID: 5082464] - PubMed
    1. Williams B, MacDonald TM, Morant SV, et al.; British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6:464–75. [PMID: 29655877] doi:10.1016/S2213-8587(18)30071-8. - DOI - PMC - PubMed
    1. Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–9. [PMID: 29129576] doi:10.1016/S2213-8587(17)30367-4. - DOI - PMC - PubMed
    1. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540–50. [PMID: 31533906] doi:10.1016/S0140-6736(19)32135-X. - DOI - PubMed